These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 11525875)
1. The role of AGEs in aging: causation or correlation. Baynes JW Exp Gerontol; 2001 Sep; 36(9):1527-37. PubMed ID: 11525875 [TBL] [Abstract][Full Text] [Related]
3. Glycoxidation and lipoxidation in atherogenesis. Baynes JW; Thorpe SR Free Radic Biol Med; 2000 Jun; 28(12):1708-16. PubMed ID: 10946212 [TBL] [Abstract][Full Text] [Related]
4. Advanced glycation end products and the progressive course of renal disease. Heidland A; Sebekova K; Schinzel R Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S100-6. PubMed ID: 11576932 [TBL] [Abstract][Full Text] [Related]
5. Advanced glycation: implications in tissue damage and disease. Gasser A; Forbes JM Protein Pept Lett; 2008; 15(4):385-91. PubMed ID: 18473952 [TBL] [Abstract][Full Text] [Related]
6. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Ramasamy R; Vannucci SJ; Yan SS; Herold K; Yan SF; Schmidt AM Glycobiology; 2005 Jul; 15(7):16R-28R. PubMed ID: 15764591 [TBL] [Abstract][Full Text] [Related]
7. Oxidative Stress and Advanced Lipoxidation and Glycation End Products (ALEs and AGEs) in Aging and Age-Related Diseases. Moldogazieva NT; Mokhosoev IM; Mel'nikova TI; Porozov YB; Terentiev AA Oxid Med Cell Longev; 2019; 2019():3085756. PubMed ID: 31485289 [TBL] [Abstract][Full Text] [Related]
8. [Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus]. Nawroth PP; Bierhaus A; Vogel GE; Hofmann MA; Zumbach M; Wahl P; Ziegler R Med Klin (Munich); 1999 Jan; 94(1):29-38. PubMed ID: 10081287 [TBL] [Abstract][Full Text] [Related]
9. Presence of dopa and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins. Fu S; Fu MX; Baynes JW; Thorpe SR; Dean RT Biochem J; 1998 Feb; 330 ( Pt 1)(Pt 1):233-9. PubMed ID: 9461515 [TBL] [Abstract][Full Text] [Related]
10. Advanced glycation end products (AGEs) and their involvement in liver disease. Hyogo H; Yamagishi S Curr Pharm Des; 2008; 14(10):969-72. PubMed ID: 18473847 [TBL] [Abstract][Full Text] [Related]
11. Advanced glycation end products: a link between periodontitis and diabetes mellitus? Gurav AN Curr Diabetes Rev; 2013 Sep; 9(5):355-61. PubMed ID: 23845077 [TBL] [Abstract][Full Text] [Related]
12. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Negre-Salvayre A; Coatrieux C; Ingueneau C; Salvayre R Br J Pharmacol; 2008 Jan; 153(1):6-20. PubMed ID: 17643134 [TBL] [Abstract][Full Text] [Related]
13. Aging and glycoxidant stress. Peppa M; Uribarri J; Vlassara H Hormones (Athens); 2008; 7(2):123-32. PubMed ID: 18477549 [TBL] [Abstract][Full Text] [Related]
14. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Vistoli G; De Maddis D; Cipak A; Zarkovic N; Carini M; Aldini G Free Radic Res; 2013 Aug; 47 Suppl 1():3-27. PubMed ID: 23767955 [TBL] [Abstract][Full Text] [Related]
15. Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure. Aronson D Med Hypotheses; 2002 Sep; 59(3):297-301. PubMed ID: 12208156 [TBL] [Abstract][Full Text] [Related]
16. Does accumulation of advanced glycation end products contribute to the aging phenotype? Semba RD; Nicklett EJ; Ferrucci L J Gerontol A Biol Sci Med Sci; 2010 Sep; 65(9):963-75. PubMed ID: 20478906 [TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Rungratanawanich W; Qu Y; Wang X; Essa MM; Song BJ Exp Mol Med; 2021 Feb; 53(2):168-188. PubMed ID: 33568752 [TBL] [Abstract][Full Text] [Related]
18. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Hori O; Yan SD; Ogawa S; Kuwabara K; Matsumoto M; Stern D; Schmidt AM Nephrol Dial Transplant; 1996; 11 Suppl 5():13-6. PubMed ID: 9044300 [TBL] [Abstract][Full Text] [Related]
19. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Valencia JV; Weldon SC; Quinn D; Kiers GH; DeGroot J; TeKoppele JM; Hughes TE Anal Biochem; 2004 Jan; 324(1):68-78. PubMed ID: 14654047 [TBL] [Abstract][Full Text] [Related]
20. Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor. Nagai R; Matsumoto K; Ling X; Suzuki H; Araki T; Horiuchi S Diabetes; 2000 Oct; 49(10):1714-23. PubMed ID: 11016456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]